A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Exclusion Criteria

• •1. Previously received gonadotropin-releasing hormone analogues (GnRH-a) for more than 12 months total duration (if GnRH-a was received for 12 months or less, then that GnRH-a must have been completed washout period prior to the first dose of study drug).
• •2. Patients who have received chemotherapy for prostate cancer;
• •3. History of surgical castration;
• •4. Received Abiraterone acetate with 3 months prior to the first dose of study drug;
• •5. Receieved molecular target therapy, immunotherapy, androgen receptor blockade, 5-alpha reductase inhibitors, estrogen, and other investigational compound with 4 weeks prior to the first dose of study drug;
• •6. Patients with known or suspected brain metastasis；
• •7. Diagnosis or treatment for another systemic malignancy within 5 years before study treatment initiation;
• •8. Patients with uncontrolled and clinically significant hypertension and diabetes;
• •9. Known hypersensitivity to SHR7280, SHR7280 excipients,；
• •10. History of immunodeficiency (including HIV infection) or organ transplantation;
• •11. Known active hepatitis B or C infection;
• •12. Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.